Published in J Clin Oncol on March 20, 2007
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 1.44
Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer (2010) 1.34
Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 1.33
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer (2010) 1.31
Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol (2009) 1.18
More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol (2014) 1.16
Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study. J Transl Med (2011) 1.15
Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev (2008) 1.10
Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer (2009) 1.03
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer (2009) 1.02
Histology-specific microRNA alterations in melanoma. J Invest Dermatol (2012) 0.99
Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol (2014) 0.98
Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98
High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol (2012) 0.97
HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene (2013) 0.96
Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch (2014) 0.96
Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol (2010) 0.95
Melanoma biomolecules: independently identified but functionally intertwined. Front Oncol (2013) 0.95
Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology. Virchows Arch (2009) 0.93
Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol (2013) 0.91
Inherited variation at MC1R and histological characteristics of primary melanoma. PLoS One (2015) 0.85
Construction and analysis of multiparameter prognostic models for melanoma outcome. Methods Mol Biol (2014) 0.84
Modifying effect of gender on the prognostic value of clinicopathological factors and Ki67 expression in melanoma: a population-based cohort study. Biol Sex Differ (2012) 0.83
Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure: impact of mole phenotype on model performance. PLoS One (2014) 0.79
Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med (2010) 0.78
Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Ann Transl Med (2015) 0.76
Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget (2015) 0.76
"Mitogenicity"-the latest and mosthilarious episode in the slapstick comedy of melanoma management. Dermatol Pract Concept (2012) 0.75
Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. PLoS One (2017) 0.75
[Mitosis in early invasive malignant melanoma. How reliable is histogenetic classification at stage pT1?]. Pathologe (2012) 0.75
Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J (2010) 0.75
How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis. J Cancer Res Clin Oncol (2015) 0.75
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol (2005) 3.33
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Med Phys (2005) 2.76
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet (2009) 2.65
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol (2013) 2.38
An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol (2012) 2.31
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Cutaneous smooth muscle neoplasms: clinical features, histologic findings, and treatment options. J Am Acad Dermatol (2002) 2.07
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol (2006) 2.05
Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev (2004) 2.05
Time of day is associated with postoperative morbidity: an analysis of the national surgical quality improvement program data. Ann Surg (2008) 2.00
Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol (2012) 2.00
Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol (2004) 1.90
Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol (2002) 1.90
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol (2013) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt (2009) 1.82
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer (2003) 1.70
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol (2002) 1.68
Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med (2006) 1.65
Diffuse optical measurement of blood flow in breast tumors. Opt Lett (2005) 1.65
A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet (2002) 1.63
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 1.50
Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol (2003) 1.50
Resection of primary leiomyosarcoma of the inferior vena cava (IVC) with reconstruction: a case series and review of the literature. J Surg Oncol (2014) 1.49
The rise in metastasectomy across cancer types over the past decade. Cancer (2014) 1.49
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol (2005) 1.46
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet (2011) 1.46
HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res (2002) 1.42
Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies. Transplantation (2012) 1.42
Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol (2004) 1.38
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol (2003) 1.34
Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer (2010) 1.34
Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol (2007) 1.31
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res (2007) 1.28
MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology (2003) 1.27
Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol (2008) 1.27
Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol (2008) 1.27
Surgery increases survival in patients with gastrinoma. Ann Surg (2006) 1.26
Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur J Cancer (2011) 1.24
Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt (2005) 1.22
Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer (2005) 1.22
Tailored versus generic interventions for skin cancer risk reduction for family members of melanoma patients. Health Psychol (2010) 1.22
Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg (2004) 1.20
Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg (2003) 1.20
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res (2006) 1.19
Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res (2006) 1.19
Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol (2008) 1.19
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17